A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT07776509. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus (SELENE 3)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.
Study identification
- NCT ID
- NCT07776509
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 500 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 20, 2026
- Primary completion
- Aug 8, 2028
- Completion
- Aug 8, 2028
- Last update posted
- Aug 19, 2026
2026 – 2028
United States locations
- U.S. sites
- 23
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Escondido | California | 92025 | — |
| Research Site | Lincoln | California | 95648 | — |
| Research Site | Walnut Creek | California | 94598 | — |
| Research Site | Fleming Island | Florida | 32003 | — |
| Research Site | Jacksonville | Florida | 32205 | — |
| Research Site | Stockbridge | Georgia | 30281 | — |
| Research Site | Woodstock | Georgia | 30189 | — |
| Research Site | Champaign | Illinois | 61822 | — |
| Research Site | Chicago | Illinois | 60640 | — |
| Research Site | Beltsville | Maryland | 20705 | — |
| Research Site | Oxon Hill | Maryland | 20745 | — |
| Research Site | Kansas City | Missouri | 64111 | — |
| Research Site | Las Vegas | Nevada | 89101 | — |
| Research Site | Somerset | New Jersey | 08873 | — |
| Research Site | Statesville | North Carolina | 28625 | — |
| Research Site | Fargo | North Dakota | 58104 | — |
| Research Site | Columbus | Ohio | 43215 | — |
| Research Site | Portland | Oregon | 97202 | — |
| Research Site | Smithfield | Pennsylvania | 15478 | — |
| Research Site | Franklin | Tennessee | 37067 | — |
| Research Site | Houston | Texas | 77043 | — |
| Research Site | Manassas | Virginia | 20110 | — |
| Research Site | Renton | Washington | 98057 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.
Recently updated Obesity or Overweight trials
Other public records listing Obesity or Overweight. Sorted by last update posted; newest first. Not a recommendation.
- NCT07784725: A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus Recruiting
- NCT07784270: A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight Not yet recruiting
- NCT07575399: Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) Recruiting
- NCT06937099: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight Recruiting
- NCT06937086: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study Recruiting
- NCT07081958: A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07776509, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2026 · Synced Aug 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07776509 live on ClinicalTrials.gov.